Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR T-cell Therapy + Glofitamab in R/R LBCL
NCT06567366Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Sep 2024
- Primary completion
- Sep 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of glofitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Ruijin Hospital. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06567366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06567366.